BOYDSense develops non-invasive breath analysis tools to measure critical biomarkers, enabling patients to monitor chronic conditions like diabetes without the discomfort and expense of traditional methods. This technology addresses the lack of affordable and pain-free monitoring solutions for millions of individuals living with chronic diseases.
Funding
$8.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for monitoring chronic diseases, such as diabetes, often involve invasive, painful, and expensive procedures, leading to infrequent monitoring and poor condition management for many individuals. A significant portion of those living with chronic diseases remain undiagnosed or lack access to affordable and pain-free monitoring solutions.
Solution
BOYDSense is developing non-invasive breath analysis technology to enable convenient and cost-effective monitoring of chronic conditions. By analyzing exhaled breath, the platform aims to provide patients with an easy way to engage with their health and monitor ongoing conditions without the need for painful or expensive equipment. The technology targets a range of health and disease conditions, with an initial focus on diabetes and glucose monitoring.
Target Audience
The primary target audience includes individuals living with chronic diseases, such as diabetes, and healthcare providers seeking affordable and accessible monitoring solutions.
Features
- Non-invasive breath analysis for biomarker measurement
- Potential applications across a range of chronic diseases, including diabetes, sepsis, and fatty liver disease
- Pain-free and easy-to-use monitoring solution
- Cost-effective alternative to traditional monitoring methods